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Abstract
Background: Seroepidemiology provides robust estimates for tracking malaria transmission when intensity is low
and useful when there is no baseline entomological data. Serological evidence of exposure to malaria vectors and
parasite contribute to our understanding of the risk of pathogen transmission, and facilitates implementation of
targeted interventions. Ab to Anopheles gambiae salivary peptide (gSG6-P1) and merozoite surface protein one
(MSP-119) reflect human exposure to malaria vectors and parasites. This study estimated malaria transmission
dynamics using serological evidence of vector and parasite exposure in southern Ghana.
Methods: Total IgG responses to both antigens in an age stratified cohort (<5, 5–14, >14) were measured from
South-eastern Ghana. 295 randomly selected sera were analyzed from archived samples belonging to a cohort study
that were followed at 3 consecutive survey months (n = 885); February, May and August 2009. Temporal variations in
seroprevalence of both antigens as well as differences between the age-stratified cohorts were determined by χ2 test
with p < 0.05 statistically significant. Non-parametric repeated ANOVA – Friedman’s test was used to test differences in
antibody levels. Seroprevalence data were fitted to reversible catalytic model to estimate sero-conversion rates.
Results: Whereas parasite prevalence was generally low 2.4%, 2.7% and 2.4% with no apparent trends with
season, seroprevalence to both gSG6-P1 and MSP119 were high (59%, 50.9%, 52.2%) and 57.6%, 52.3% and 43.6%
in respective order from Feb. to August. Repeated measures ANOVA showed differences in median antibody levels across
surveys with specific significant differences between February and May but not August by post hoc Dunn’s
multiple comparison tests for gSG6-P1. For MSP119, no differences were observed in antibody levels between
February and May but a significant decline was observed from May to August. Seroconversion rates for gSG6-P1
increased by 1.5 folds from February to August and 3 folds for MSP119.
Conclusion: Data suggests exposure to infectious bites may be declining whereas mosquito bites remains high.
Sustained malaria control efforts and surveillance are needed to drive malaria further down and to prevent
catastrophic rebound. Operational factors for scaling up have been discussed.
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* Correspondence: Kingsbadu@gmail.com
1Department of Immunology, Noguchi Memorial Institute for Medical
Research, College of Health Science University of Ghana, LG581, Legon,
Accra, Ghana
Full list of author information is available at the end of the article
© 2015 Badu et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Badu et al. Parasites & Vectors  (2015) 8:251 
DOI 10.1186/s13071-015-0861-y
Background
Malaria elimination has again been accepted as the goal
of malaria control efforts with thirty-two out of the
remaining ninety-nine malaria endemic countries cur-
rently implementing malaria elimination strategies [1].
As international efforts towards malaria elimination in-
crease, accurate data on transmission intensity will be
crucial for directing control efforts, developing and test-
ing new control tools, and predicting the effects of these
interventions under various conditions [2]. It has been
suggested that during the pre-elimination phase, the
focus of monitoring and evaluation of impact of inter-
ventions must shift from surveying health system indica-
tors such as number of malaria cases and associated
mortality to measuring malaria transmission intensity
and infection [3-5]. However, very low malaria transmis-
sion intensity and the non-uniform transmission occur-
ring after periods of extensive control [6,7] highlights
important limitations associated with the current tools
for measuring malaria transmission intensity. The lack
of sensitivity of current malaria transmission tools con-
stitutes a major bottleneck for malaria elimination ef-
forts [3,5].
The entomological inoculation rates (EIR), the product
of man biting rates (Ma) and the sporozoite rate (SR,
proportion of mosquitoes carrying sporozoites), is the
gold standard for measuring malaria transmission inten-
sity. It is the most direct way of detecting human exposure
to infectious bites and mosquito population monitoring.
However under conditions of very low malaria transmis-
sion the EIR suffers from well recognized limitations [2].
Notably, the intrinsic uncertainty in measuring Ma with
methods such as human landing catches, resting collec-
tions, pyrethrum spray catches, and Centers for Disease
Control and Prevention (CDC) light traps are all subject
to operator-related variability, such that results may not
be reproducible or accurately reflective of the overall local
population, and the need for standardized methods for
measuring both Ma and SR [8,9] limit the precision and
accuracy of EIR and its potential for measuring a change
in transmission. This is especially so at low transmission
intensities, where it is difficult to catch sufficient mosqui-
toes. The limitations associated with measuring malaria
transmission by vector mosquitoes are expected to be-
come even more pronounced as ongoing implementation
of available control methods, including indoor residual
spraying (IRS) and insecticide-treated nets (ITNs), drive
down mosquito and malaria endemicity levels [10].
Parasite prevalence (PR), is a well-known metric that
is used to estimate the proportion of the human popula-
tion who are found to be carrying parasites in their
blood [11]. The accuracy of outcome varies with the
method used [12]. However, it generally becomes less re-
liable as a tool for measuring the intensity of malaria
transmission when parasitemia is low [13]. As a result,
more sensitive and standardized metrics are needed to as-
sess transmission intensity in real time, to assess interven-
tions, to acquire data necessary for planning appropriate
control programs in areas of low transmission [13,3].
Immuno-epidemiological assays based on human
humoral responses to P. falciparum and Anopheles anti-
gens are potentially valuable for robust transmission
measurement [12-15]. In particular, the Merozoite Sur-
face Protein 1 (MSP 119) seroconversion rates has been
shown to correlate with malaria transmission intensity
(EIR), and to depict malaria endemicity by identifying
hotspots of higher malaria transmission [15-18]. MSP-
119 seroprevalence and antibody level has proven to be
sensitive in discriminating small spatial scales in malaria
exposures at varying altitudes, age groups, and distance
to Anopheles breeding habitats [14,19,20].
The use of antibodies to Anopheles salivary proteins as
a proxy for human exposure to vector bites and risk of
parasite transmission is a promising endeavor. This phe-
nomena rests on the concept that Anopheles vectors in-
jects salivary proteins containing a cocktail of bioactive
compounds including vasodilators and anticoagulants
[21], which mitigate vertebrate host’s defense mechanism
such as hemostais, inflammation and thus facilitate
blood feeding [22]. Some of the components of the bio-
active compounds are antigenic and, elicits adaptive
humoral response in the vertebrate host. The level of
human exposure to Anopheles bites, have thus been
found to correlate with the level humoral response to
anti-salivary proteins [23,24]. This assay has so far been
applied as an epidemiological marker of vector exposure
and risk of pathogen transmission in exposed popula-
tions. So far, the utility of this application has been dem-
onstrated in leishmaniasis [25], Chagas disease [26] and
recently in malaria from western Kenya and elsewhere
[20,24-26]. Due to the logistical difficulty in extracting
whole saliva from mosquitoes and the possible cross re-
activity between common epitopes within the dipteral
group the recombinant protein (gSG6) specific to the
Anopheles genus was isolated and purified for the assay
[27-29]. Recently a synthetic peptide, the gambiae saliv-
ary gland peptide 1 (gSG6-P1) based on the recombinant
protein with an enhanced Anopheles specificity and anti-
genecity has been developed and validated [20,30]. The
synthetic peptide has standardized the assay and guaran-
teed high reproducibility such that it is possible to com-
pare results from one lab to the other and from one
region to the other. Antibody reactivity to this peptide
shows promising characteristics as a biomarker for hu-
man biting by Anopheles mosquitoes. So far increases in
gSG6-P1 specific antibody levels correlated with in-
creased rainfall in a region of very low mosquito expos-
ure and rapid decreases in these levels were observed in
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individuals after ITNs were introduced in areas of high
malaria transmission [31,32]. The gSG6-P1 marker ap-
pears to have several characteristics of an ideal bio-
marker; firstly its very specific to the Anopheles genus
with no relevant cross-reactivity with epitopes from
other proteins or vectors of protozoan parasites [30,32].
Its synthetic nature largely ensures high reproducibility
of the assay and it induces specific host humoral re-
sponse which correlates with the level of exposure to
An. gambiae bites.
We explored the utility of the Anopheline salivary pep-
tide (gSG6-P1) in comparison with MSP-119, a well known
malaria antigen, to examine the fine temporal variations
in vector and parasite exposure in an area of low malaria
transmission but high vector exposure. The ability to de-
tect temporal changes in malaria transmission intensity
will enable us to sensibly deploy scarce resources in a tar-
geted focal control to yield maximum community or
country benefits and speed malaria elimination.
Methods
Archived plasma samples for the current study were
obtained from an earlier cohort study conducted in
Asutuare and its surrounding areas. The cohort was se-
lected from a relatively small geographic area within
5 km radius with non-significant differences in malaria
exposure, and malaria antibody genetic markers de-
scribed in detail by Adu et al. [33]. Thus, malaria vari-
ation in the cohort, in respect of geographic location
was considered homogeneous. Asutuare is a sub-district
of Shai Osudoku district, (formerly Dangbe west district)
in Greater Accra of Ghana. It is a semi-rural area about
40 km northeast of Accra, the capital of Ghana. The
district has a surface area of 1,442 km2 and a population
size of 122,836 (population and housing census, 2010
(http://www.ghanadistricts.com/pdfs/2010_pop_census_
districts.pdf ). The population is typically scattered in
small satellite villages of about two thousand people. The
district usually has two rainy seasons in a year, beginning
from April to July and October to December. Malaria
transmission is low but perennial, and peaks slightly dur-
ing and immediately after the major rainy seasons and is
lowest during the dry seasons [34]. It is estimated that in-
dividuals near the district capital are exposed to about 7.5
infective bites in the rainy season (Personal communica-
tion), and 98% of the infections are due to P. falciparum
[34]. Historically there was a huge sugar processing
company with corresponding commercial farms of
sugar cane. The community thus has a network of ca-
nals created for irrigation schemes. This potentially ex-
poses inhabitants to mosquito bites all year round. It is
not surprising that the area has been a site for piloting
malaria related interventions since the 1990s [35].
Overall, the sum of 560 participants between the ages of
one and thirty were enrolled for the original study in
2009; these were followed up in three cross-sectional
community-based surveys to collect blood samples for
laboratory analysis; in February towards the end of the dry
season, May near the peak of rainy season and August
representing snap shots of the perennial transmission in
the year. For the purpose of this study, sera from 295
subjects were randomly chosen and assayed from each
time point.
Sample size
Sample size was determined by using the binomial
model to estimate the confidence interval (CI) [36]. Be-
cause antibody prevalence to the salivary gland protein
and the MSP1 were unknown in the area, the antibody
prevalence of CSP (25%) previously reported in the co-
hort [37] was used as the antibody prevalence to esti-
mate the sample size. The sample size with a 95% CI
and precision level of 5% was estimated according to the
formulae below: In this equation, n is the sample size, z
is the critical value of the standard normal distribution
at the 5% level (1.96), p is the prevalence of antimalarial
CSP antibody, q = 1 – p, and d is the precision level. The
population size was estimated to be 2,000. The mini-
mum sample size was estimated to be 288.
no ¼ ZaPq
d2
Ethical approval
The study used sera samples archived from an earlier
cohort study conducted in 2009.
Ethical clearance for the main study was granted by
the Institutional Review Board (IRB) of the Noguchi Me-
morial Institute for Medical Research (NMIMR). Study
participants or their parents/legal guardians gave written
informed consent, which permitted storage for future
malaria studies, before enrolment into the study. For the
present study, analysis of archived sera was blinded.
Anopheles gambiae salivary antigen
Bioinformatic tools were used to design and optimize
the specificity and immunogenicity of the Anopheles
gambiae salivary peptide (gSG6-P1) as previously re-
ported [30,20]. Protein sequences were sent to Genepep
(St-Jean de Vedas, France) which synthesized and puri-
fied (>95%) the peptide. This was then shipped to Ghana
in lyophilized form.
Testing for Total IgG antibodies to An. gambiae antigen
(gSG6-P1)
Serologic testing of human exposure to gSG6-P1 was
achieved using Enzyme-Linked Immunosorbent Assay
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(ELISA) as previously reported [20]. Briefly, gSG6-P1
peptide (20 μg/mL) was used to coat Maxisorp microti-
tre plates (Roskilde, Denmark) and incubated at 37°C
for 21/2 hrs and then washed. Blocking buffer (0.5%
Casein 0.05% Tween20) was added for 1 hr at room
temperature. Sera from participants were diluted at an
optimized dilution of 1:20 diluent, and kept at 4°C over
night. Polyclonal goat anti-human IgG antibody conju-
gated to horse radish Peroxidase (Nordic Immunology,
Tilburg, Netherlands) at a dilution of 1:10,000 in PBS
was used to detect Anti-gSG6- P1 IgG. A peroxidase
substrate ABTS (Kirkegaard & Perry Laboratories Inc.,
Gaithersburg, MD) was then added after washing and
kept at room temperature for 50 mins. Enzymatic reac-
tion was stopped with 4 N H2SO4. Optical density
(OD) was then read at 450 nm on a spectrophotometer.
Test sera were evaluated in duplicates with a corre-
sponding third well containing no antigen (ODn), a
blank well to control for non-specific reactions in the
sera and the reagents. IgG levels were determined as
final OD computed for each serum as the mean OD
value (with antigen) minus the OD value without anti-
gen (ODn-blank well). For the purposes of quality as-
surance, intra- and inter-assay disparity of control
samples was below 20%. Sera whose duplicates had a
coefficient of variation (CV) 20% and above were ex-
cluded from the analysis. The mean OD of unexposed
controls (from the Europe, N = 30) plus 3 SD was used
as cut-off value for seropositivity.
Measurement of anti-human IgG antibodies for PfMSP119
(FVO) antigen
Total IgG antibody to PfMSP119 was measured by indir-
ect ELISA as previously described [14]. The expression
and purification of the PfMSP119 recombinant protein
has also been described [14,20]. Assay plates (Maxisorp,
Roskilde, Denmark) were coated with 0.5 μg PfMSP1 re-
combinant protein and incubated overnight at 4°C. After
blocking, test sera were added in duplicate wells. HRP
conjugate of goat antihuman IgG (KPL, Gaithersburg,
MD) was added after incubation. Then ABTS (Kirkegaard
& Perry Laboratories Inc., Gaithersburg, MD) was added
and incubated for 1 h at 22°C. The OD measurements
were taken at 414 nm on a spectrophotometer (Spectra-
MAX 340PC, Molecular Devices Corporation). Duplicate
optical densities were averaged and normalized against a
positive control. The cut off for seropositivity was an OD
three standard deviations or more above the mean OD ob-
tained in samples from 25 Europeans with no history of
previous malaria exposure.
Data analysis
Seroprevalence was defined as the number of positive re-
sponders out of the total number of participants tested.
The temporal variations in seroprevalence of both anti-
gens as well as differences between the age-stratified co-
horts were determined by χ2 test with p < 0.05
considered statistically significant. The non-parametric
repeated ANOVA – Friedman’s test was used to test if
median antibody levels were different across different
survey months (Feb, May and August) as well as the dif-
ferent age strata. The Post Hoc Dunn’s multiple com-
parison tests was used to test specific differences in
seroprevalence between specified survey months and age
groups. Age specific MSP-119 and gSG6-P1 seropreva-
lence data was fitted to a simple reversible catalytic model
using the maximum likelihood method that assumes a
binomial error distribution; Pt = λ / (λ + ρ) [1 – exp (−
(λ + ρ) t)] where Pt is the proportion of individuals aged
t that is seropositive, Lambda λ is the annual rate of
seroconversion and ρ is the annual rate of reversion to
seronegative. This was done to investigate the relation-
ship between force of vector and parasite exposure with
age. All data were analysed and graphed using Graph-
Pad Prism software (San Diego, CA, USA).
Results
Study population and parasite prevalence
A total of 295 subjects had data available for all the 3
surveys (Feb, May and Aug) and thus all analysis were
based on the 295 selected samples. 27% out of the sub-
jects were less than 5 yrs whilst the majority of the study
subjects were between the ages of 5 and 14. Only 12% of
the participants in the selected cohort were in the in the
age bracket of 15–29 (Table 1).
Number of participants, parasite prevalence and antigen
specific seroprevalence
Parasite prevalence was generally low with no particular
seasonal trends observed across the three contact
months (Table 1). Within the age groups, parasite preva-
lence by microscopy rose from an average of 1.7% in <
5 year group to a two-fold increase (3.4%) in the 5–14
year group but a complete absence (0%) in the adult
group. However, Chi square analysis revealed no signifi-
cant differences in parasite prevalence when the three
age groups were compared (Table 1).
Table 1 Total number tested in age stratification, parasite
prevalence and antigen specific seroprevalence
Age Parasite prevalence (%) χ2 P value
N (%) Feb May Aug
<5 80(27) 2.5 1.3 1.3 0.51 0.77
5-14 179(61) 2.8 3.9 3.4 0.34 0.8
15-29 36(12) 0.0 0.0 0.0 ND ND
χ2 1.01 2.63 2.05
P value 0.60 0.27 0.36
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Antigen specific seroprevalence
Exposures to the Anopheles gambiae salivary protein
(gSG6-P1) were high throughout the three survey months,
although a 10% decline in seroprevalence was observed
between 1st and 2nd survey months (February and
May), this was just at the threshold of statistical signifi-
cance (χ2 = 3.6, DF =1, p =0.05). There was a significant
but gradual decline in exposures to the blood stage P.
falciparum merozoite surface proteins (MSP119.),
MSP119 specific seroprevalence observed in 1
st survey
declined by 5% in the 2nd survey and a further 10% in
August (Table 2).
Correlation of antigen specific seroprevalence and
parasite prevalence with age
The spearman correlation analysis revealed an inverse re-
lationship between P. falciparum prevalence and age for
all three survey months although this was not strong to
achieve statistical significance; Feb (r = −0.30; p =0.46),
May (r = −0.05; p =0.93) and August (r = −0.39; p =0.32).
High exposures to the salivary gland peptide corresponded
to strong association with age observed in the first and
second survey months (Figure 1), however these expo-
sures gradually declined with a non significant correlation
with age in the third survey (r = 0.16; p = 0.11). gSG6-P1
responses had very similar trends compared with that ob-
served in MSP119 which also had a strong correlation in
the first survey with a gradual decline in the second and
third surveys (Figure 1).
Comparison of antigen-specific median antibody levels at
the cohort population level
Median antibody levels of gSG6-P1 and MSP119 antigens
as measured in optical densities in the cohort at all sur-
vey months across age groups were above the threshold
of the unexposed group. Median levels of anti gSG6-P1
antibody showed significant differences in antibody
levels in mosquito exposure between the first survey
(February 2009) and second (May 2009) survey months,
detecting temporal variations in vector exposure among
the cohorts at different time points. The Friedman’s test
(Repeated measures ANOVA and non parametric) re-
vealed significant differences in antibody levels to gSG6-
P1 between the first, second and third survey months at
the population level. (F = 33.97; p < 0.0001) as well as
post hoc Dunn’s multiple comparison tests between Feb
and May: (p < 0.0001), Feb and August (p < 0.0001), but
not May and August (p > 0.5) (Figure 2).
Similar to the differences in gSG6-P1, the Friedman’s
statistic detected overall significant differences in anti
MSP119 levels compared across survey months (F = 14.98;
p = 0.0006). However, post hoc analysis revealed no signifi-
cant differences between first and second (February and
May) survey months (p >0.05) but significant decline were
observed in the antibody levels between the second and
third (May-August) survey months (p < 0.05) (Figure 2).
Age-stratified Cohort and Median antibody levels
Generally, median antibody levels to all antigens differed
among the age groups throughout the surveys (Kruskal-
Wallis H test) (Figure 3). However, post hoc Dunn’s
multiple comparisons test revealed differences between
specific pairs of age groups.
Kruskal-Wallis H statistic revealed significant differ-
ences in anti gSG6-P1 level across all age-stratified co-
horts and survey months; Feb (H = 17.49; p = 0.0002),
May (H =11.09; p = 0.0039) and August (H = 10.43;
Table 2 Comparison of antigen specific seroprevalence at
the population level in different survey months
Antigen- specific Seroprevalence χ2 s
Feb May August
gSG6-P1 59.8 50.9 52.2 4.18 0.123
PfMSP119 57.6 52.3 43.6 6.84 0.033
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Figure 1 Correlation of antigen specific seroprevalence and parasite prevalence with age.
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p <0.0054) with increasingly higher antibody levels. How-
ever, the Dunn’s multiple comparison tests (post hoc test)
between specific pairs of age-stratified cohorts showed in-
triguing differences: consistently, there were significant
differences between < 4 and the 5–14 age groups across
all survey months, Feb (p < 0.001) May (p < 0.01) and
Aug (p < 0.01) with higher antibody levels observed in
the 5–14 year cohorts. However, there were no differ-
ences seen in the antibody levels of anti-gSG6P1 in the
5–14 and the >14 age group in the first and second
Figure 2 Comparison of median antigen specific antibody levels in within the study cohort.
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Figure 3 Age-stratified comparisons of antibody levels to specific antigen in contact month.
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survey months (P > 0.05), a decline in between the third
survey with the > 15 year cohort having lower gSG6-P1
levels but this was not statistically significant (Figure 3).
Median antibody levels to the merozoite surface protein
(MSP119) increased significantly between <5 and 5–14 age
groups in the first and second survey months but not
the third (Figure 3). In respective order Feb (H = 20.01;
p <0.0001) May (H = 9.43; p <0.01) August (H = 4.99;
p > 0.05). Similar to gSG6-P1, there were no differences
in the antibody levels observed between the 5–14 and
the adult age-groups throughout the three survey
months.
The force of exposure to vector bites and parasite over
time
The force of exposure to both antigens (gSG6-P1(Figure 4)
and MSP119 (Figure 5)) tested increased significantly with
age at all contact months, however the rate at which in-
dividuals change from being seronegative to seroposi-
tive differed with each antigen and survey month,
gSG6-P1(Figure 4), MSP119 (Figure 5) . Generally, sero-
conversion rates (λ) (SCR) for gSG6-P1 and MSP119
gradually increased from February to August, The force
of exposure to vector bites increased 1.5 fold from Feb-
ruary to August (Figure 4). MSP119 SCR increased mar-
ginally between 1.5 folds to 3 folds from February to
May then to August. Sero-reversion rates (ρ), also re-
corded a somewhat corresponding increase (Figure 5).
Discussion
Metrics of malaria transmission change on different tem-
poral scales, mirroring among other things the changes in
vector exposure, parasite infections in humans, as well as
the dynamics of changing human immunity. The key
component in deciding the appropriateness of malaria
transmission metrics as end points for measuring changes
in transmission is determined not only by costs, precision,
and accuracy, but also by the intrinsic variability of the
metric across space and time [38]. Using age specific sero-
prevalence data, antibody density and seroconversion
rates, it is possible to identify temporal variations in
mosquito and parasite exposure to show the variation in
the intensity of malaria transmission that would otherwise
go undetected by parasite prevalence due to apparent low
transmission in the Asutuare area.
The use of serological markers of vector and parasite
exposure to track changes in malaria transmission over
time has several competitive advantages over other met-
rics. Chiefly, serological markers are more sensitive and
robust [15,16,14]. For equivalent parasite rates, sero-
logical markers generate seroprevalence that is higher
than the parasite prevalence revealing active transmis-
sion in progress over a period of time that would other-
wise be deemed as interrupted transmission [13,39]. In
the current study whereas parasite prevalence was well
below 5% throughout the year; equivalent seroprevalence
of gSG6-P1 and MSP119 was 40% and above. Similar
findings have been reported elsewhere. In Somalia, when
no parasites were detected both in wet and dry seasons
after screening more than one-thousand people, 17.9%
and 19.3% of MSP119 seroprevalence was found respect-
ively [13]. Similarly, in the uphill dwellers of the Western
Kenyan highlands it is reported that when parasite
prevalence was well below 10%, seroprevalence of gSG6-
P1 and MSP119 reached peaks above 50% [20].
Serological markers, in particular gSG6-P1, are robust
in tracking temporal changes in vector exposure and risk
of pathogen transmission in the younger population
under intense transmission intensity [20,27,28,31,32,40].
In the adult population however, there seem to be an
immuno-tolerance to the recombinant protein version
(gSG6) where higher exposures result in declining im-
mune response, this has been explained as desensitization
of the salivary proteins to the immune system of the
adults [41]. It is known to be highly antigenic in naïve in-
dividuals with only transient exposure and wanes rapidly
in the absence of continuous exposure, this has variously
been corroborated in Senegal and Angola [31,42,43].
Sagna et al. studied human immune response to gSG6-P1
salivary peptide in five communities in northern Senegal
where malaria transmission has been described as low,
with the An. gambiae s. l. as the principal vector. They
Figure 4 Seroconversion rate gSG6-P1.
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observed a significant increase in IgG levels to gSG6-P1
during the peak exposure to Anopheles bites, and a cor-
responding decrease right after the end of the exposure
season [31]. Moreover, IgG levels to gSG6-P1 varied
considerably according to the villages, discriminating
the heterogeneity of Anopheles exposure between vil-
lages [20,31].
In the current study it was observed that Total IgG
anti-gSG6-P1 levels showed significant differences be-
tween February and May but showed sustained high
levels in August. Asutuare is a sugar-cane growing area;
a cash crop that thrives in water logged areas, thus the
area has several irrigation schemes that virtually flood
the area all year round exposing inhabitants to high vec-
tor exposure. High vector exposure as evidenced from
the anti-gSG6-P1 responses was observed in the month
of February, a relatively dry month, this may be due to
lagged effect of high rainfall recorded two-three months
earlier in 2008 [37]. Meteorological variables have dis-
tinct patterns and effects on malaria transmission due to
specific lagged correlations and most time series studies
have provided evidence of an association between rain-
fall and mosquito abundance, typically at a single lag of
0, 1 or 2 months depending on the mosquito species
[44]. The Anopheles gambiae, a principal malaria vector
in the district, requires relatively shallow and transient
breeding aquatic habitat and therefore its abundance
does not peak immediately after heavy rainfall but must
tarry for the flooding waters to recede.
MSP119 Age-specific seroprevalence has been used to
estimate seroconversion rates (SCR) as a measure of mal-
aria transmission intensity. Earlier studies in Tanzania
have shown that these estimates are tightly correlated with
EIR measurement [15,16,45]. Age seroprevalence curves
reflect different levels of transmission intensity. In low
transmission settings development of antibodies is slow
and prevalence is higher by the adult population, whereas
in a high transmission area, much of the population will
be seropositive even at a younger age [18]. The SCR of
parasite exposure based on MSP119 seroprevalence has
been described as an equivalent of the force of infection
and correlated with the entomological inoculation rate.
This measures the rate of parasite exposure in the popula-
tion with age (or time) [15,16]. In the current study the
MSP119 SCR increased about 3 fold from February to Au-
gust. Although seroprevalence decreased approximately
8% (gSG6-P1) and 14% (MSP119) at the population level
from the February to August (Table 2), the SCR is a func-
tion of age and exposure. It is noteworthy that, when the
data was stratified into age cohorts, seroprevalence to
both antigens increased significantly from the 1–4 to the
5–14 year groups in all survey months (Figure 3) except
for MSP119 in August. Moreover, although parasite preva-
lence showed a non-significant decline from 2.7% (May)
to 2.4% (August), age stratifications revealed that parasite
prevalence increased with age in the paediatric population
which happens to be 88% of the total study population
(Table 1). Parasite prevalence within the >5 year group in-
creased from 2.5%, 1.3% and 1.3% in first (Feb), Second
(May) and third (August) survey months to 2.8%, 3.9%
and 3.4% respectively. Thus this finding confirms the in-
herent ability of the SCR to reflect changes in transmis-
sion in terms of exposure and time.
The force of exposure to vector bites as seen in sero-
prevalence and antibody levels in study participants in-
creased 1.5 fold from February to August. This implies
that the aggressiveness of vector bites increased or the
Anopheles population density increased. It has been sug-
gested that the gSG6-P1 is a reliable marker for measur-
ing human–vector contact [32]. Possibly it depicts the
human vector contact like the ma measured in EIR esti-
mation, this is because human immune response to
gSG6-P1 increases and decreases sharply following high
and low vector exposure seasons, and transient exposure
in naïve individuals, this has been observed by other sci-
entist elsewhere [32,42]. In Lobito, a malaria-endemic
coastal city of Western Angola, Papa Drame and co-
workers conducted a longitudinal evaluation of the efficient
use of insecticide treated net (ITNs) using parasitological,
entomological and immunological assessments in children
Figure 5 Seroconversion rate MSP119.
Badu et al. Parasites & Vectors  (2015) 8:251 Page 8 of 11
as well as adults in 2010 [32,46]. A significant decrease in
anti-gSG6-P1 IgG levels was observed just after the effi-
cient use of ITNs with a subsequent rise in IgG levels to
the peptide about four months after when the correct
usage of ITN had waned. They thus concluded that the
gSG6-P1 “provides a valuable tool in malaria vector control
based on a real measurement of human-vector contact” It
has also been observed to correspond with malaria endem-
icity at the population level discriminating villages with
higher malaria exposure [27,20,47]. It is thus plausible to
state that gSG6-P1 has the inherent ability to track chan-
ging vector exposure [32]. It has been shown that gSG6-P1
is able to detect differences in vector exposure in different
age groups and distance from Anopheles breeding sites
[20], rapid buildup and decay of antibody levels [42]. The
particular usefulness of gSG6-P1 is its ability to show dif-
ferences in the short term exposure as has been seen in
this study.
Parasite prevalence (PR) in the current study was
generally low, with no exposure in the adult popula-
tion >15 years, this has been reported by other scien-
tists working in the same area [44]. The prevalence
was determined solely by microscopy which may have
underestimated the prevalence [48]. Parasite preva-
lence generally tends to be lower in adult population
due to their well-developed immunity [49]. However,
the strength of the relationship between PR and age
depends on the endemicity or the transmission inten-
sity of the area. Similar to this study, no significant re-
lationship was observed between PR and age in the
uphill residents of western Kenyan highlands but with
low malaria transmission intensities. However, there
was a strong inverse relationship in the valley dwellers
with relatively higher transmission intensity [14,50].
Under low transmission intensity, specifically when
parasite prevalence is below 1–5%, it is complicated to
use PR as a metric to detect changes in transmission
or evaluate impact of interventions [51]. This has been
attributed to several factors associated with the PR.
Fundamentally, PR is inherently imprecise because
parasite densities fluctuate over the course of a single
infection [38], again the accuracy (sensitivity and spe-
cificity) of parasite detection in an infected blood de-
pends on the number of parasites/μ of blood with the
probability of detecting parasite decreasing at low
densities. Both microscopy and RDTs fail to detect
subpatent infections when the parasite density is less
than 250 parasites per μl [12]. In addition, parasite
densities are strongly affected by the recent history of
antimalarial drug intake and parasite resistance to
those drugs [15]. Thus parasite prevalence is only a
discrete measure that represents a snap shot of com-
plex dynamic interactions which may need intensive
multiple sampling all year round to be accurate.
Seroprevalence and seroconversion rates of vector
(gSG6-P1) and parasite proteins (MSP119) provide a use-
ful sero-surveillance tool for tracking malaria transmis-
sion intensity. In order to scale.
Up this approach, three major issues need to be con-
sidered: the source of antigens, collection of study sam-
ple and laboratory processing to generate seroprevalence
data. The salivary gland antigen is a short sequence syn-
thetic peptide that can be synthesized in-house or by
any commercial peptide company. Its synthetic nature
generates reproducible results that can be compared
across different laboratories [14,30]. Collection of blood
in sero-epidemiological surveys used to be very cumber-
some especially when antibodies needed to be quanti-
fied. However, this has been simplified in recent times,
since antibodies can be eluted from filter paper. This has
made sample collection and storage uncomplicated [52].
Lastly, the Enzyme Linked-Immuno-sorbent Assay (ELISA)
is high throughput, standardizable assay, which is cheap,
easy to perform and also generates objective reproducible
results. Tusting et al. [38], actually quantified the cost per
sample with ELISA as USD$0.5 and with a turnover of
1000 samples per week. Other methodologies like the
multiplex suspended bead assay (Luminex™) and protein
microarrays [53] have the added advantage of analyzing
several antigens per sample and require smaller amounts of
sera however; these are relatively expensive due to the cap-
ital intensive equipments.
Conclusion
Using antibody levels to gSG6-P1 and MSP119, seropreva-
lence and seroconversion rates (SCR) together with para-
site prevalence, we have identified low parasite prevalence,
high vector exposure and small changes in malaria trans-
mission intensity from February through May and then to
August 2009. Seroconversion rates for gSG6-P1 increased
by 1.5 folds from February to August and 3 folds for
MSP119. Possibly, exposure to infectious bites may be de-
clining whereas mosquito bites remains high. Malaria
transmission in Asutuare as well as many other areas in
Africa where endemicity is low needs careful monitoring
with sensitive and robust tools to ascertain progress and
to forestall a potential catastrophic rebound.
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